Market Overview:
The global cutaneous fibrosis drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cutaneous fibrosis, rising awareness about available treatment options, and growing demand for better-quality drugs. The global cutaneous fibrosis drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into corticosteroids, anti-fibrotic drugs, and immunoglobulins. Corticosteroids are expected to account for a major share of the global cutaneous fibrosis drugs market in 2018 owing to their high efficacy in treating various forms of skin diseases. Anti-fibrotic drugs are also expected to witness significant growth during the forecast period due to their ability to prevent or reverse tissue damage caused by excessive collagen production. Immunoglobulins are used as an adjunctive therapy for severe cases of cutaneous fibrosis and are expected to experience high growth during the forecast period.
Product Definition:
Cutaneous fibrosis is a medical condition characterized by the development of excessive scar tissue in the skin. This can lead to significant impairment of function, including difficulty moving and deformity. There are a number of different drugs that can be used to treat this condition, each with its own benefits and risks. The importance of cutaneous fibrosis drugs depends on the individual case, as well as on the severity of the symptoms.
Corticosteroids:
Corticosteroids are the group of drugs whose action is to reduce inflammation by suppressing the release of cytokines by immune cells. Corticosteroid treatment helps in reducing damage to various organs, including lungs, kidneys, and brain.
Anti-Fibrotic Drugs:
Anti-fibrotic drugs are used to treat patients suffering from liver cirrhosis, chronic pancreatitis, and scleroderma. Anti-fibrotics are also used in the treatment of pulmonary embolism and thrombophlebitis.
Application Insights:
The hospitals application segment held the largest share of 66.0% in 2017. The cutaneous fibrosis drugs are used for various indications such as atopic dermatitis, chronic idiopathic urticaria, and others. In addition, increasing incidences of hospital-acquired diseases is expected to boost market growth during the forecast period.
The pharmacies application segment is anticipated to witness a lucrative CAGR over the forecast period owing to growing awareness about availability of low-cost medicines coupled with rising health consciousness among consumers in emerging countries including China India and Brazil who prefer purchasing these medicines from pharmacies due to their affordability as compared to hospitals or other healthcare facilities where they are prescribed by doctors only if necessary (Ref). Increasing usage of online medical stores by patients suffering from chronic diseases including cancer and diabetes for purchasing cutaneous fibrosis drugs will further propel market growth during the study period (2017 - 2030) (Ref).
Regional Analysis:
North America dominated the global cutaneous fibrosis drugs market in 2017. The presence of key players, favorable reimbursement policies, and increasing R&D activities are some of the factors responsible for its large share. In addition, high prevalence of chronic skin diseases such as eczema and psoriasis is also driving growth in this region. According to an article published by National Institute of Health (NIH), around 17 million people suffer from psoriasis in the U.S.
Growth Factors:
- Increasing incidence of cutaneous fibrosis
- Growing awareness about the available treatment options for cutaneous fibrosis
- Rising demand for better and more effective treatment options for cutaneous fibrosis
- Availability of government funding and private investment for research on cutaneous fibrosis drugs
- Technological advancements in the field of drug development
Scope Of The Report
Report Attributes
Report Details
Report Title
Cutaneous Fibrosis Drugs Market Research Report
By Type
Corticosteroids, Anti-Fibrotic Drugs, Immunoglobulins
By Application
Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer, Novartis, Sanofi, Merck, Roche, GlaxoSmithKline, Bayer, Boehringer Ingelheim, Horizon Pharma, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Cutaneous Fibrosis Drugs Market Report Segments:
The global Cutaneous Fibrosis Drugs market is segmented on the basis of:
Types
Corticosteroids, Anti-Fibrotic Drugs, Immunoglobulins
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Sanofi
- Merck
- Roche
- GlaxoSmithKline
- Bayer
- Boehringer Ingelheim
- Horizon Pharma
- Bristol-Myers Squibb
Highlights of The Cutaneous Fibrosis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Corticosteroids
- Anti-Fibrotic Drugs
- Immunoglobulins
- By Application:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cutaneous Fibrosis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cutaneous fibrosis drugs are medications used to treat a variety of skin conditions, including cutaneous fibrosis. These drugs work by reducing the amount of scarring and inflammation that can occur in the skin.
Some of the key players operating in the cutaneous fibrosis drugs market are Pfizer, Novartis, Sanofi, Merck, Roche, GlaxoSmithKline, Bayer, Boehringer Ingelheim, Horizon Pharma, Bristol-Myers Squibb.
The cutaneous fibrosis drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cutaneous Fibrosis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cutaneous Fibrosis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cutaneous Fibrosis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cutaneous Fibrosis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cutaneous Fibrosis Drugs Market Size & Forecast, 2018-2028
4.5.1 Cutaneous Fibrosis Drugs Market Size and Y-o-Y Growth
4.5.2 Cutaneous Fibrosis Drugs Market Absolute $ Opportunity
Chapter 5 Global Cutaneous Fibrosis Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cutaneous Fibrosis Drugs Market Size Forecast by Type
5.2.1 Corticosteroids
5.2.2 Anti-Fibrotic Drugs
5.2.3 Immunoglobulins
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cutaneous Fibrosis Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cutaneous Fibrosis Drugs Market Size Forecast by Applications
6.2.1 Hospitals Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cutaneous Fibrosis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cutaneous Fibrosis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cutaneous Fibrosis Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Cutaneous Fibrosis Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cutaneous Fibrosis Drugs Market Size Forecast by Type
9.6.1 Corticosteroids
9.6.2 Anti-Fibrotic Drugs
9.6.3 Immunoglobulins
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cutaneous Fibrosis Drugs Market Size Forecast by Applications
9.10.1 Hospitals Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cutaneous Fibrosis Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Cutaneous Fibrosis Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cutaneous Fibrosis Drugs Market Size Forecast by Type
10.6.1 Corticosteroids
10.6.2 Anti-Fibrotic Drugs
10.6.3 Immunoglobulins
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cutaneous Fibrosis Drugs Market Size Forecast by Applications
10.10.1 Hospitals Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cutaneous Fibrosis Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cutaneous Fibrosis Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cutaneous Fibrosis Drugs Market Size Forecast by Type
11.6.1 Corticosteroids
11.6.2 Anti-Fibrotic Drugs
11.6.3 Immunoglobulins
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cutaneous Fibrosis Drugs Market Size Forecast by Applications
11.10.1 Hospitals Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cutaneous Fibrosis Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Cutaneous Fibrosis Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cutaneous Fibrosis Drugs Market Size Forecast by Type
12.6.1 Corticosteroids
12.6.2 Anti-Fibrotic Drugs
12.6.3 Immunoglobulins
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cutaneous Fibrosis Drugs Market Size Forecast by Applications
12.10.1 Hospitals Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cutaneous Fibrosis Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cutaneous Fibrosis Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cutaneous Fibrosis Drugs Market Size Forecast by Type
13.6.1 Corticosteroids
13.6.2 Anti-Fibrotic Drugs
13.6.3 Immunoglobulins
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cutaneous Fibrosis Drugs Market Size Forecast by Applications
13.10.1 Hospitals Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cutaneous Fibrosis Drugs Market: Competitive Dashboard
14.2 Global Cutaneous Fibrosis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Sanofi
14.3.4 Merck
14.3.5 Roche
14.3.6 GlaxoSmithKline
14.3.7 Bayer
14.3.8 Boehringer Ingelheim
14.3.9 Horizon Pharma
14.3.10 Bristol-Myers Squibb
